Skip to main content

Stroke and Dementia

Stroke and dementia can produce suprapontine neurogenic lower urinary tract dysfunction.[5] In patients with stroke or dementia who void with low PVR, stable renal function, and no urologic complications, the typical suprapontine pattern is detrusor overactivity with coordinated voiding, low storage pressures, and low upper-tract risk.[1][5]

See Neurogenic Lower Urinary Tract Dysfunction for the general framework.

Epidemiology​

  • Stroke. About 795,000 strokes occur annually in the US, including approximately 610,000 first events and 185,000 recurrent events.[20] Urinary incontinence affects roughly 40–60% of patients admitted after stroke, about 25% at discharge and about 15% at one year.[4] EAU cites LUTS in 57–83% at one month, with 71–80% spontaneous recovery by six months; bladder emptying usually improves within about 75 days.[5] Persistent incontinence correlates with a poor prognosis, and post-stroke incontinence relates to cognitive dysfunction and stroke severity.[5] A 2024 meta-analysis of 21 observational studies (n = 7,327) pooled an incidence of 38%.[6] A separate meta-analysis of 24 studies found post-stroke urinary incontinence independently associated with higher mortality, both unadjusted (HR 5.1, 95% CI 3.9–6.7) and after adjustment for confounders (HR 2.2, 95% CI 1.8–2.7), in both ischemic and hemorrhagic stroke; the authors identified evidence of publication bias, though the association persisted after correcting for it.[15]
  • Early pattern. Urgency incontinence, frequency and nocturia (detrusor overactivity) predominate; acute retention occurs mainly after large or severe strokes and usually resolves.[5]
  • Dementia (Alzheimer, vascular, mixed). Alzheimer disease is about 80% of cases. Urinary incontinence is about three times more frequent than in age-matched patients without dementia and rises with severity; OAB or urgency incontinence with detrusor overactivity is the usual urodynamic finding.[5]
  • Combined stroke and dementia and age-related LUTS (BPH in men, GSM in women) is the clinical reality in most patients.

Pathophysiology​

  • Suprapontine lesion (cortex, subcortex, basal ganglia) disinhibits the pontine micturition center, producing detrusor overactivity with preserved coordination.
  • Storage pressures are often low, and upper-tract risk is much lower than in spinal cord injury or spina bifida, but risk classification still depends on emptying, complications and any coexisting disease.[3]
  • Cognitive and motor impairment add a functional incontinence layer; recognition of the urge, transfer speed, clothing management, caregiver response time all affect continence as much as detrusor behavior.
  • Normal-pressure hydrocephalus (NPH) is a suprapontine cause presenting with the classic triad of gait ataxia, cognitive decline and urinary incontinence, with ventriculomegaly and normal CSF opening pressure; it can be idiopathic or follow a prior CVA or hemorrhage. A prospective series of 55 patients with idiopathic NPH found urinary incontinence in 90.9% (urgency incontinence in 74.5%), and a separate prospective cohort of 23 patients reported questionnaire-based improvements after ventriculoperitoneal shunting in urgency, urge incontinence, ability to perform physical activities, and quality of life.[13][14] NPH is a treatable dementia mimic: evaluate older patients with new incontinence plus gait or cognitive change. In a 2025 double-blind trial of 99 patients selected by gait response to CSF drainage, open-valve shunting improved gait at three months, while Overactive Bladder Questionnaire scores changed by −3.3 versus −1.5 points with placebo (between-group difference −1.9 points, 95% CI −4.0 to 0.1).[21]

Evaluation​

The AUA/SUFU guideline risk-stratifies NLUTD patients (low, moderate, high, unknown) and re-stratifies when symptoms change.[1] The typical suprapontine picture (storage symptoms, insignificant PVR, detrusor overactivity)[5] is usually low risk, and AUA/SUFU advises against routine upper-tract imaging, renal function assessment or multichannel urodynamics in low-risk patients ; an elevated PVR after stroke makes initial risk unknown. In patients with NLUTD after an acute neurologic event, AUA/SUFU calls for risk stratification once the neurologic condition has stabilized ; at initial evaluation, patients with unknown-risk NLUTD should undergo upper-tract imaging, renal function assessment, and multichannel urodynamics .[1] EAU recommends video-urodynamics when invasive testing is done in neurological patients.[5]

When urodynamics is performed after stroke, the pattern can evolve within the first month. In a series of 106 patients with ischemic stroke tested at admission and 63 of those patients retested at 30 days, admission studies showed a normal pattern in 15%, detrusor overactivity in 56%, detrusor overactivity with impaired contractility in 14%, and detrusor underactivity in 15%; among the 63 retested at 30 days, the same categories were 30%, 48%, 6%, and 16%, respectively.[16] Repeat urodynamics when the clinical picture changes after an early post-stroke study.

Baseline:

  • History, with explicit attention to functional status, cognition, caregiver support, mobility, fall risk, and current medications (especially those with anticholinergic burden).
  • Bladder or incontinence diary: distinguishes urge versus functional versus mixed.
  • UA, PVR.
  • Risk-directed testing. AUA/SUFU advises against routine upper-tract imaging, renal function assessment, and multichannel urodynamics in initial low-risk NLUTD . Elevated PVR, recurrent UTI, stones, or new or worsening symptoms prompt risk re-stratification; unknown-risk patients need renal function assessment, upper-tract imaging, and multichannel urodynamics . Once moderate risk is confirmed, assess symptoms and renal function annually and image the upper tracts every 1–2 years . Evaluate hematuria and suspected obstruction according to their findings.[1]

Management​

When refractory OAB justifies procedural therapy in cognitively intact patients, see Intradetrusor OnabotulinumtoxinA and Sacral Neuromodulation; the Ileal Conduit is an occasional palliative option for intractable incontinence-related skin breakdown.

Behavioral and caregiver-directed​

  • Scheduled toileting (prompted voiding). A caregiver may offer toileting every 2–3 hours and around meals when cognition limits independent voiding. Five small trials (355 older adults) gave suggestive but inconclusive evidence for fewer episodes in the short term, with no long-term data.[7] The 2019 Cochrane review found small, heterogeneous post-stroke trials; Canadian Stroke Best Practices (2025) recommends considering timed or systematic voiding .[4][19]
  • Environmental modifications. Bedside commode, elevated toilet seats, clothing with velcro or elastic, clear nighttime path to the bathroom, night lights.
  • Fluid and caffeine timing. Use a bladder diary to identify nocturnal polyuria; when present, reduce evening fluids (none for two hours before bedtime) and limit evening caffeine.[25]
  • Bowel regimen. Constipation worsens urinary symptoms in older patients.
  • Pelvic-floor muscle training. For post-stroke patients able to participate, Canadian Stroke Best Practices (2025) says it may improve voiding frequency and incontinence ; EAU rates the direct evidence as limited.[19][5]
  • Transcutaneous electrical nerve stimulation. The 2025 Canadian Stroke Best Practices says it may be considered to reduce post-stroke incontinence .[19]

Pharmacologic​

  • β3-adrenergic agonists (mirabegron, vibegron). AUA/SUFU permits antimuscarinics, beta-3 agonists or both , with no mandatory class order.[2]
  • Antimuscarinics. The 2023 AGS Beers Criteria list antimuscarinic bladder drugs among strongly anticholinergic agents to avoid in dementia or cognitive impairment (and in delirium).[8] Lower-CNS-penetrating agents (e.g., trospium) are sometimes chosen when one is unavoidable, but no antimuscarinic is established as cognitively risk-free; avoid oxybutynin IR in particular. EAU advises considering a switch to a beta-3 agonist if cognition worsens.[5] Review each agent's contribution to the patient's anticholinergic burden score, including bladder drugs, first-generation antihistamines, tricyclic antidepressants, and anticholinergic bowel agents; cumulative exposure is associated with cognitive adverse effects.[8]
  • Cholinesterase inhibitors. In a Medicare claims cohort of 524,975 adults with dementia starting cholinesterase inhibitors, 5.07% had a new OAB diagnosis or a prescription for an antimuscarinic or mirabegron within six months; this composite endpoint was more frequent with donepezil than rivastigmine (adjusted HR 1.13, 95% CI 1.08–1.28).[9] Antimuscarinics oppose cholinergic dementia treatment, but a 2026 retrospective cohort of 2,693 adults aged 65 years or older with dementia who started an OAB drug within 60 days of newly starting a cholinesterase inhibitor found inconclusive one-year associations for delirium and falls with antimuscarinics versus mirabegron (adjusted HR 1.35, 95% CI 0.64–2.86 and 0.66, 95% CI 0.20–2.15, respectively).[10] Before adding an antimuscarinic, review whether a recently started cholinesterase inhibitor is the cause.
  • Mirabegron or vibegron cautions. Check blood pressure and PVR before and after starting; with either drug, monitor for retention in patients with bladder outlet obstruction or concurrent antimuscarinic therapy.[17][22] Mirabegron can raise blood pressure; its prescribing information advises periodic monitoring and does not recommend use when systolic blood pressure is ≥180 mm Hg or diastolic blood pressure is ≥110 mm Hg.[17] In neurological patients the evidence is still limited, though a standard 50 mg dose showed no cognitive worsening in Parkinson disease.[5]
  • Alpha-blockers (men with coexisting BPH): orthostatic hypotension and falls are the concern after stroke; Beers advises against nonselective peripheral alpha-1 blockers in patients with syncope.[8]
  • Duloxetine. For women with coexisting stress-predominant mixed incontinence unresponsive to conservative treatment who want to avoid invasive care, EAU offers duloxetine where licensed , with counselling about adverse effects.[23]
  • Desmopressin. Nocturia indication; avoid in frail older patients due to hyponatremia risk (Beers 2023 advises against its use for nocturia or nocturnal polyuria).[8]

Catheter-based management​

  • Indwelling catheters. Avoid routine placement after acute ischemic stroke because of catheter-associated UTI risk (AHA/ASA Class III: Harm, Level C-LD). For retention or another indication, assess necessity daily and remove the catheter as soon as possible, returning to assisted toileting or pads when feasible.[24][19]
  • CIC is rarely feasible in moderate dementia; appropriate in selected stroke patients with intact cognition and caregiver assistance.
  • Condom catheter (men) is practical for overnight management in selected cases. Bacteriuria frequency differs between continuous and night-only use; in one prospective nursing-home cohort, 87% of 30 continuous users had at least one episode during observation.[18] Cognitive impairment requires extra vigilance for unrecognized strangulation or skin breakdown.

Intradetrusor onabotulinumtoxinA​

  • Reasonable in stroke patients with refractory OAB and preserved cognition; AUA/SUFU allows onabotulinumtoxinA in oral-refractory NLUTD other than SCI or MS .[2]
  • Caution in patients who cannot perform CIC: post-injection retention may require indwelling catheter. Patients who void spontaneously must be counseled about retention and possible CIC beforehand .[2]
  • Generally avoided in moderate-to-severe dementia for the same reason.

Sacral neuromodulation (SNM)​

  • Reasonable in post-stroke patients with refractory OAB and preserved cognition .[2]
  • In dementia, assess whether the patient or caregiver can operate the device and attend programming. Future MRI needs require checking the exact generator, lead and scan conditions; MRI-conditional systems do not make imaging a categorical reason to avoid sacral neuromodulation.[5]

Reconstructive surgery​

  • Very uncommon in stroke / dementia. Upper-tract risk is low; reconstruction is rarely justified by QoL alone in a cognitively impaired patient with a short or uncertain trajectory.
  • Urinary diversion or ileal conduit is an occasional option in the setting of devastating skin breakdown from incontinence and inability to toilet, particularly in bed-bound patients. Usually a palliative or caregiver-oriented decision.

Common Scenarios​

Acute stroke with urinary retention​

  • Acute retention can occur immediately after stroke. Insert a catheter, trial removal as mobility and cognition recover.
  • Persistent retention beyond the acute rehab phase warrants PVR check, imaging, and, in men, BPH evaluation.

Post-stroke OAB in a patient with coexisting BPH​

  • Pragmatic path: α-blocker and β3 agonist first; urodynamics if refractory or equivocal; outlet surgery only for documented obstruction.
  • Avoid aggressive antimuscarinic use in patients at elevated fall / delirium risk.

Dementia with functional incontinence​

  • Functional interventions dominate. Scheduled toileting, clothing modifications, caregiver education, pads / briefs. Medication review to reduce anticholinergic burden.
  • Treat the reversible. Symptomatic UTI, constipation, diuretic dosing, sleep apnea. Bacteriuria without new genitourinary symptoms or systemic signs (fever, hemodynamic instability) warrants observation and reassessment rather than antibiotics, including in women who cannot report symptoms.[11][12]

Nursing-home patient with urinary incontinence​

  • Avoid "placement decision driven by incontinence" where possible; pads and scheduled toileting often restore manageable care at home.
  • Reasonable pharmacologic trial: β3 agonist; avoid chronic anticholinergics.

Post-stroke retention in an older man​

Commonly a "BPH and stroke" presentation. A weak stream may reflect detrusor underactivity, obstruction or both. A 2024 systematic review of four high-risk-of-bias prostate-surgery studies in 691 men with prior stroke reported worsened continence in 21–50% across two studies; discuss that risk during consent.[27]

Clinical Correlations for the Reconstructive Urologist​

  • Upper-tract risk is low; QoL and caregiver burden dominate. Resist escalating to reconstructive procedures in cognitively impaired patients without durable benefit.
  • Individualize medication choice and minimize anticholinergic burden; discuss possible cognitive adverse effects.
  • Functional incontinence. When cognition or mobility contributes to leakage after stroke, use toileting schedules, accessible clothing, mobility aids, and caregiver support.[19]
  • Acute-phase retention after stroke is less frequent than storage symptoms, and bladder emptying often improves within about 75 days; reassess voiding and PVR before planning long-term drainage.[5]
  • Mixed BPH and post-stroke OAB. Consider pressure-flow urodynamics before outlet surgery when obstruction or detrusor contractility remains uncertain.[1][26]
  • Quality-of-life goals come first. What does the patient (and caregiver) value? Continuing independence? Avoiding falls? Skin preservation? These drive the plan more than the urodynamic phenotype.
  • Trajectory matters. Reconstruction with a long maintenance burden (catheterization, metabolic surveillance and symptom-triggered investigations) rarely serves a patient with progressing dementia.

See Also​

References​

1. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Diagnosis and Evaluation." J Urol. 2021;206(5):1097–1105. doi:10.1097/JU.0000000000002235

2. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Treatment and Follow-Up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

3. Panicker JN, Fowler CJ, Kessler TM. "Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management." Lancet Neurol. 2015;14(7):720–732. doi:10.1016/S1474-4422(15)00070-8

4. Thomas LH, Coupe J, Cross LD, et al. "Interventions for treating urinary incontinence after stroke in adults." Cochrane Database Syst Rev. 2019;2(2):CD004462. doi:10.1002/14651858.CD004462.pub4

5. European Association of Urology. "EAU Guidelines on Neuro-Urology" (limited update, March 2026). uroweb.org/guidelines/neuro-urology

6. Wang S, Kang H, Wang Q, et al. "Incidence and influencing factors of urinary incontinence in stroke patients: A meta-analysis." Neurourol Urodyn. 2024;43(3):680–693. doi:10.1002/nau.25398

7. Eustice S, Roe B, Paterson J. "Prompted voiding for the management of urinary incontinence in adults." Cochrane Database Syst Rev. 2000;(2):CD002113. PMID: 10796861 doi:10.1002/14651858.CD002113

8. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. "American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults." J Am Geriatr Soc. 2023;71(7):2052–2081. doi:10.1111/jgs.18372

9. Masurkar PP, Chatterjee S, Sherer JT, et al. "Risk of overactive bladder associated with cholinesterase inhibitors in dementia." J Am Geriatr Soc. 2022;70(3):820–830. doi:10.1111/jgs.17579

10. Tucker SB, Love BL, Okeke CM, et al. "Association Between Cholinesterase Inhibitor-Overactive Bladder Antimuscarinic Prescribing Cascade and Risk of Delirium and Falls Among Individuals Living With Dementia." J Am Geriatr Soc. 2026;74(5):1314–1325. doi:10.1111/jgs.70386

11. Nicolle LE, Gupta K, Bradley SF, et al. "Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America." Clin Infect Dis. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121

12. Siddiqui NY, Ackerman AL, Advani SD, et al. "Management of Asymptomatic Bacteriuria in Adult Female Populations." Urogynecology (Phila). 2025;31(9):827–845. doi:10.1097/SPV.0000000000001731

13. Krzastek SC, Bruch WM, Robinson SP, et al. "Characterization of lower urinary tract symptoms in patients with idiopathic normal pressure hydrocephalus." Neurourol Urodyn. 2017;36(4):1167-1173. doi:10.1002/nau.23084

14. Krzastek SC, Robinson SP, Young HF, et al. "Improvement in lower urinary tract symptoms across multiple domains following ventriculoperitoneal shunting for idiopathic normal pressure hydrocephalus." Neurourol Urodyn. 2017;36(8):2056-2063. doi:10.1002/nau.23235

15. John G, Bardini C, Mégevand P, Combescure C, Dällenbach P. "Urinary incontinence as a predictor of death after new-onset stroke: a meta-analysis." Eur J Neurol. 2016;23(10):1548-1555. doi:10.1111/ene.13077

16. Pizzi A, Falsini C, Martini M, Rossetti MA, Verdesca S, Tosto A. "Urinary incontinence after ischemic stroke: clinical and urodynamic studies." Neurourol Urodyn. 2014;33(4):420-425. doi:10.1002/nau.22420

17. RemedyRepack Inc. "Mirabegron extended-release tablets: prescribing information." DailyMed. Published May 25, 2026; section 5.1. Label.

18. Ouslander JG, Greengold B, Chen S. "External catheter use and urinary tract infections among incontinent male nursing home patients." J Am Geriatr Soc. 1987;35(12):1063-1070. doi:10.1111/j.1532-5415.1987.tb04922.x

19. Heart and Stroke Foundation of Canada. "Canadian Stroke Best Practice Recommendations: Rehabilitation, Recovery and Community Participation Following Stroke, Part Two: Delivery of Stroke Rehabilitation to Optimize Functional Recovery, 7th Edition Update 2025." 2025. Section 10: Bladder and Bowel Function.

20. Centers for Disease Control and Prevention. "Stroke Facts." Updated October 24, 2024. CDC.

21. Luciano MG, Williams MA, Hamilton MG, et al. "A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus." N Engl J Med. 2025;393(22):2198–2209. doi:10.1056/NEJMoa2503109

22. Sumitomo Pharma America, Inc. "GEMTESA (vibegron) tablets: prescribing information." DailyMed. Updated April 1, 2025; section 5.1. Label.

23. European Association of Urology. "EAU Guidelines on Non-neurogenic Female LUTS." 2026 update; sections 4.2.4.b.2 and 4.3.3.c.4. Guideline.

24. Prabhakaran S, Gonzalez NR, Zachrison KS, et al. "2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association." Stroke. 2026;57(8):e316–e436. doi:10.1161/STR.0000000000000513

25. Nguyen LN, Randhawa H, Nadeau G, et al. "Canadian Urological Association best practice report: Diagnosis and management of nocturia." Can Urol Assoc J. 2022;16(7):E336–E349. doi:10.5489/cuaj.7970

26. European Association of Urology. "EAU Guidelines on the Management of Non-neurogenic Male LUTS." 2026 update; section 4.12. Guideline.

27. Charalampous I, Tsikopoulos I, Mitkani C, et al. "Does Surgical Treatment for Benign Prostate Enlargement (BPE)-Related Bladder Outlet Obstruction (BOO) Benefit Patients with Central Nervous System Diseases? A Systematic Review." J Clin Med. 2024;13(19):5846. doi:10.3390/jcm13195846